title: Re: Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. M. R. Smith, R. A. Morton, K. G. Barnette, P. R. Sieber, S. B. Malkowicz, D. Rodriguez, M. L. Hancock and M. S. Steiner. J Urol 2010;184:1316-1321.
authors.forename: Ruth E
authors.initials: RE
authors.lastname: Langley
authors.forename: Fay H
authors.initials: FH
authors.lastname: Cafferty
authors.forename: Philip A
authors.initials: PA
authors.lastname: Pollock
authors.forename: Patricia
authors.initials: P
authors.lastname: Price
authors.forename: Paul D
authors.initials: PD
authors.lastname: Abel
mesh_terms: D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D050723:Fractures, Bone / Q000139:chemically induced* / Q000517:prevention & control*; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D012307:Risk Factors; D017312:Toremifene / Q000627:therapeutic use*
chemical_list: D050071:Bone Density Conservation Agents; D007987:Gonadotropin-Releasing Hormone; D017312:Toremifene